PMID- 26727349
OWN - NLM
STAT- MEDLINE
DCOM- 20171229
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 57
IP  - 8
DP  - 2016 Aug
TI  - Prognostic value of lymphocyte/monocyte ratio in advanced Hodgkin lymphoma: 
      correlation with International Prognostic Score and tumor associated macrophages.
PG  - 1839-47
LID - 10.3109/10428194.2015.1110745 [doi]
AB  - We studied the prognostic significance of the absolute lymphocyte/monocyte count 
      ratio (ALC/AMC), its contribution to the prognostic value of the International 
      Prognostic Score (IPS), and evaluated if ALC/AMC could serve as a proxy for the 
      frequency of CD68 + tumor-associated macrophages (TAMs) in 101 patients with 
      advanced Hodgkin lymphoma (HL). The receiver operating characteristic (ROC) curve 
      identified best cut-off values of 2.0 for ALC/AMC and 25% for CD68 + TAM. 
      Patients with ALC/AMC < 2, IPS > 2 and > 25% CD68 + TAM had an inferior overall 
      survival (OS) and event-free survival (EFS). Spearman's test also uncovered a 
      significant correlation between the ALC/AMC and TAM. Multivariate analysis 
      identified ALC/AMC < 2, IPS > 2 and > 25% CD68 + TAM as poor prognostic factors 
      of OS and EFS. After evaluating ALC/AMC and IPS, we stratified patients into 
      three progressively-worse-outcome groups (low-risk: 0 risk factors; intermediate: 
      1 risk factor; high: 2 risk factors). Our study encourages the combination of 
      ALC/AMC with IPS, for refining risk prediction in advanced HL patients.
FAU - Jakovic, Ljubomir R
AU  - Jakovic LR
AD  - a Clinic of Hematology, Clinical Center of Serbia , Serbia ;
AD  - b Faculty of Medicine, University of Belgrade , Serbia ;
FAU - Mihaljevic, Biljana S
AU  - Mihaljevic BS
AD  - a Clinic of Hematology, Clinical Center of Serbia , Serbia ;
AD  - b Faculty of Medicine, University of Belgrade , Serbia ;
FAU - Andjelic, Bosko M
AU  - Andjelic BM
AD  - a Clinic of Hematology, Clinical Center of Serbia , Serbia ;
AD  - b Faculty of Medicine, University of Belgrade , Serbia ;
FAU - Bogdanovic, Andrija D
AU  - Bogdanovic AD
AD  - a Clinic of Hematology, Clinical Center of Serbia , Serbia ;
AD  - b Faculty of Medicine, University of Belgrade , Serbia ;
FAU - Perunicic Jovanovic, Maja D
AU  - Perunicic Jovanovic MD
AD  - c Department of Histopathology , Clinical Center of Serbia , Serbia ;
FAU - Babic, Dragan D
AU  - Babic DD
AD  - d Institute of Medical statistics and Informatics, Faculty of Medicine University 
      of Belgrade , Serbia ;
FAU - Bumbasirevic, Vladimir Z
AU  - Bumbasirevic VZ
AD  - e Institute of Histology and Embryology, Faculty of Medicine University of 
      Belgrade , Serbia.
LA  - eng
PT  - Journal Article
DEP - 20160104
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (CD68 antigen, human)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, CD/metabolism
MH  - Antigens, Differentiation, Myelomonocytic/metabolism
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Hodgkin Disease/*blood/*mortality/pathology/therapy
MH  - Humans
MH  - Immunohistochemistry
MH  - Lymph Nodes/pathology
MH  - Lymphocyte Count
MH  - Lymphocytes/*pathology
MH  - Macrophages/*pathology
MH  - Male
MH  - Middle Aged
MH  - Monocytes/*pathology
MH  - Neoplasm Staging
MH  - Prognosis
MH  - ROC Curve
MH  - Radiotherapy, Adjuvant
MH  - Retrospective Studies
MH  - Risk Assessment/methods
MH  - Risk Factors
MH  - Salvage Therapy/methods
MH  - Tumor Microenvironment
MH  - Young Adult
OTO - NOTNLM
OT  - ALC/AMC
OT  - Advanced Hodgkin lymphoma
OT  - IPS
OT  - TAM
EDAT- 2016/01/05 06:00
MHDA- 2017/12/30 06:00
CRDT- 2016/01/05 06:00
PHST- 2016/01/05 06:00 [entrez]
PHST- 2016/01/05 06:00 [pubmed]
PHST- 2017/12/30 06:00 [medline]
AID - 10.3109/10428194.2015.1110745 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2016 Aug;57(8):1839-47. doi: 10.3109/10428194.2015.1110745. Epub 
      2016 Jan 4.